Giant Biogene (02367.HK) Hotness Analysis: Market Dynamics Amid Performance Growth and Industry Controversies

This analysis is based on East Money App’s hot list (Hong Kong Stock Market Popularity List) information. Giant Biogene (02367.HK), a leading enterprise in the recombinant collagen sector, has recently become a market focus due to performance growth and industry controversies [0]. The company’s first-half 2025 revenue and net profit both achieved double-digit growth, with its core brand KeyiMei performing outstandingly, but it is affected by negative product news [6][9]. Multiple institutions maintain overweight or buy ratings, with target prices higher than the current stock price [5][8].

Giant Biogene is a leader in China’s recombinant collagen sector and listed on the Hong Kong Stock Exchange in November 2022 [0]. First-half 2025 revenue was RMB 3.113 billion (+22.5% YoY), net profit was RMB 1.182 billion (+20.2% YoY) [6]. Its core brand KeyiMei generated revenue of RMB 1.23 billion (+101% YoY), showing strong brand recognition [2]. Management expects full-year sales growth of 25%-28%, and HSBC forecasts net profit growth of 23.5% to RMB 2.547 billion [0][9].

Since mid-December 2024, the stock price has fallen by approximately 12%, and rebounded 3.31% to HKD 60.95 in June 2025 [0]. The controlling shareholder plans to spend at least RMB 200 million on share purchases to boost confidence [7].

The collagen concept has become a hot spot in the capital market, regarded as the “next-generation hyaluronic acid” [3]. Controversies between the company and Huaxi Bio have increased attention, involving the authenticity of product ingredients [0]. Earlier, “Dr. Big Mouth” was banned from speaking for questioning product fraud [4].

1. Brand Power Drives Growth
   : KeyiMei’s 101% YoY growth is the core driver [2].
2. Positive Analyst Consensus
   : Institutional target prices range from HKD 69 to HKD 81.9, higher than the current stock price [5][8].
3. Favorable Industry Trends
   : The collagen market is expanding, benefiting leading enterprises [3].

• Brand Reputation Risk
  : Negative news about KeyiMei may affect its image [9].
• Stock Price Volatility Risk
  : Short-term uncertainty leads to stock price fluctuations [0].
• Increased Competition Risk
  : Industry competition may compress profit margins [3].

• Market Growth Dividend
  : The collagen industry is growing, and the company is expected to expand [3].
• Shareholder Purchase Boost
  : The controlling shareholder’s purchase plan sends positive signals [7].
• Technological Advantages Empower
  : Bioactive ingredient technology supports new product development [0].

Giant Biogene (02367.HK) has strong fundamentals and brand power. Despite facing product controversies and stock price fluctuations, analyst consensus is positive and industry trends are favorable. Investors need to pay attention to brand reputation risks and seize long-term opportunities from the growth of the collagen market.